CAPRCapricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne muscular dystrophy, a severe muscle-wasting disorder with significant unmet medical need. The company also develops engineered exosomes through its StealthX platform, which is designed to deliver nucleic acids, proteins, and small molecules for applications in vaccinology and other therapeutic areas. Capricor Therapeutics operates in the healthcare and life sciences sector, where its work spans regenerative medicine, rare-disease treatment, and next-generation biologics. The company’s current portfolio centers on advanced clinical and preclinical programs that aim to address complex conditions through targeted biological mechanisms rather than traditional small-molecule approaches.